Global orthopedic sales totaled $59 billion in 2023, an increase of 6.5% compared to 2022. Read our regularly updated analysis of the orthopedic market, including sales forecasts for all segments, company revenue and insight into key trends.
The Numbers
Stay up to date on the orthopedic market’s 2Q performance in 2024 as we update this post with company sales data and industry developments.
The U.S. remains the world’s largest orthopedic market by revenue, but companies see significant opportunities for international growth.
November 14, 2024
,
Mike Evers
Mid-tier growth companies Treace Medical, Paragon 28 and OrthoPediatrics are among the fastest-growing companies in orthopedics.
November 14, 2024
,
The company grew in the mid-single digits, driven by its broad product portfolio and increasing U.S. market penetration.
November 11, 2024
,
This additional funding will propel EpiBone’s pipeline development of regenerative products for skeletal reconstruction.
November 8, 2024
,
The company grew in the mid-single digits on a pro forma basis in the third quarter of 2024 as it shifted back to offense.
November 8, 2024
,
The company grew 63% on a reported basis in the third quarter of 2024 as it anniversaried its merger with NuVasive.
November 7, 2024
,
The largest joint replacement companies are averaging double-digit knee replacement sales growth outside the U.S. over the last two years.
December 10, 2024
,
Proceeds will support patient access to metal-free OSSIOfiber surgical implants, which provide a fixation solution while leaving nothing permanent behind.
December 2, 2024
,
We examine the 2024 performance of three companies among the fastest-growing in orthopedics: Treace Medical, Paragon 28 and OrthoPediatrics.
November 18, 2024
,
The company grew in the high-teens in the third quarter of 2024, as its wide-ranging portfolio insulated it from market headwinds.
November 14, 2024
,
Mid-tier growth companies Treace Medical, Paragon 28 and OrthoPediatrics are among the fastest-growing companies in orthopedics.
November 14, 2024
,
The company grew in the mid-single digits, driven by its broad product portfolio and increasing U.S. market penetration.
November 11, 2024
,
This additional funding will propel EpiBone’s pipeline development of regenerative products for skeletal reconstruction.
November 8, 2024
,
The company grew in the mid-single digits on a pro forma basis in the third quarter of 2024 as it shifted back to offense.
November 8, 2024
,
The company grew 63% on a reported basis in the third quarter of 2024 as it anniversaried its merger with NuVasive.
November 7, 2024
,
The company’s orthopedic sales grew in the mid-single digits but headwinds in China will have an ongoing impact into 2025.
